Autologous Muscle Precursor Cell Therapy

About Muvon Therapeutics

MUVON Therapeutics is pioneering a personalized cell therapy platform for skeletal muscle regeneration, initially targeting stress urinary incontinence (SUI) in women. The company's technology involves isolating, expanding, and re-injecting a patient's own muscle precursor cells to restore muscle function. Having successfully completed a Phase II trial, MUVON is positioned to advance its lead program while leveraging its platform for other muscle-wasting conditions. Backed by academic roots, key leadership appointments, and non-dilutive grants, the company is building towards establishing a new standard of care in regenerative medicine.

Therapeutic Areas